ReviewRadiation oncology (London, England)2014
Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options.
Review in Radiation oncology (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol.Clinical and translational radiation oncology · 2023Article
- Efficacy of local therapy to metastatic foci in nasopharyngeal carcinoma: large-cohort strictly-matched retrospective study.Therapeutic advances in medical oncology · 2022Article
- Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role forUrologic oncology · 2021Article
- Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonistInternational journal of cancer · 2019Article
- A risk-based approach to identifying oligometastatic disease on imaging.International journal of cancer · 2019Review
- Palliative radiotherapy to dominant symptomatic lesion in patients with hormone refractory prostate cancer (PRADO).Radiation oncology (London, England) · 2019Article
- Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Article
- Radiotherapy cannot prolong overall survival of young prostate cancer patients with bone metastases.Journal of translational medicine · 2016Article
- PSMA-Based Detection of Prostate Cancer Bone Lesions With ¹⁸F-DCFPyL PET/CT: A Sensitive Alternative to (⁹⁹m)Tc-MDP Bone Scan and Na¹⁸F PET/CT?Clinical genitourinary cancer · 2016Article
- Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.The Prostate · 2016Review
- [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results.Radiation oncology (London, England) · 2016Article
- Pattern of Tumour Spread of Common Primary Tumours as Seen on Magnetic Resonance Imaging.Pathology oncology research : POR · 2016Article
- Erratum: Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options.Radiation oncology (London, England) · 2015Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are various subgroups of patients with metastatic prostate cancer: polymetastatic, oligometastatic, or oligo-recurrent cancers whose progression follows different courses and for whom there are different treatment options. Knowledge of tumor dissemination pathways and different genetic and epigenetic tumor profiles, as well as their evolution during disease progression, along with new diagnostic and therapeutic advances has allowed us to address these situations with local ablative treatments such as stereotactic body radiation therapy or stereotactic radiosurgery. These treatments provide high rates of local control with low toxicity in metastatic spread for primary cancers including those of pulmonary, digestive, and renal origin, while these types of treatments are still emerging for cancers of prostatic origin. There are several retrospective studies showing the effectiveness of such treatments in prostate cancer metastases, which has led to the emergence of prospective studies on the issue and even some phase II studies intended to prevent or delay systemic treatments such as chemotherapy. Here we collect together and review these past experiences and the studies currently underway. These types of radiotherapy treatments redefine how we approach extracranial metastatic disease and open up new possibilities for combination therapy with new systemic treatment agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.